Aldehyde-sequestering drugs: Tools for studying protein damage by lipid peroxidation products

Toxicology

Volumn 181-182, Issue , 2002, Pages 229-236

  Burcham, Philip C ^a   Kaminskas, Lisa M ^a   Fontaine, Frank R ^a   Petersen, Dennis R ^b   Pyke, Simon M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

4 Hydroxynonenal; Acrolein; Dihydralazine; Hydralazine; Lipid peroxidation; Malondialdehyde

Indexed keywords

2,3 UNSATURATED ALDEHYDE; 4 HYDROXYNONENAL; ACROLEIN; ALDEHYDE; AMINE; AMINOGUANIDINE; CARNOSINE; DIHYDRALAZINE; HYDRALAZINE; HYDRAZONE DERIVATIVE; MALONALDEHYDE; PHTHALAZINE DERIVATIVE; PYRIDOXAMINE; SCAVENGER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG TARGETING; LIPID PEROXIDATION; LIVER CELL; MACROMOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; TISSUE LEVEL;

ACROLEIN; ALDEHYDES; ANIMALS; CARNOSINE; GUANIDINES; HUMANS; HYDRALAZINE; LIPID PEROXIDATION; OXIDATION-REDUCTION; PROTEINS; PYRIDOXAMINE;

LETHRINIDAE;

EID: 4243088697     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(02)00287-1     Document Type: Article

References (55)

1. Abe H. Role of histidine-related compounds as intracellular proton buffering constituents in vertebrate muscle. Biochemistry (Mosc.). 65:2000;757-765.
2. Al-Abed Y., Bucala R. Efficient scavenging of fatty acid oxidation products by aminoguanidine. Chem. Res. Toxicol. 10:1997;875-879.
3. Ando Y., Brannstrom T., Uchida K., Nyhlin N., Nasman B., Suhr O., Yamashita T., Olsson T., El Salhy M., Uchino M., Ando M. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J. Neurol. Sci. 156:1998;172-176.
4. Agardh E., Hultberg B., Agardh C. Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. Curr. Eye Res. 21:2000;543-549.
5. + channels. Eur. J. Pharmacol. 361:1998;43-49.
6. Boor P.J., Nelson T.J. Biotransformation of the cardiovascular toxin, allylamine, by rat and human cardiovascular tissue. J. Mol. Cell. Cardiol. 14:1982;679-682.
7. Boor P.J., Sanduja R., Nelson T.J., Ansari G.A. In vivo metabolism of the cardiovascular toxin, allylamine. Biochem. Pharmacol. 36:1987;4347-4353.
8. Booth A.A., Khalifah R.G., Hudson B.G. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem. Biophys. Res. Commun. 220:1996;113-119.
9. Booth A.A., Khalifah R.G., Todd P., Hudson B.G. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J. Biol. Chem. 272:1997;5430-5437.
10. Burcham P.C., Kuhan Y.T. Diminished susceptibility to proteolysis after protein modification by the lipid peroxidation product malondialdehyde: inhibitory role for crosslinked and noncrosslinked adducted proteins. Arch. Biochem. Biophys. 340:1997;331-337.
11. Burcham P.C., Kerr P.G., Fontaine F. The antihypertensive hydralazine is an efficient scavenger of acrolein. Redox Rep. 5:2000;47-49.
12. Calingasan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem. 72:1999;751-756.
13. Chasovnikova L.V., Formazyuk V.E., Sergienko V.I., Boldyrev A.A., Severin S.E. The antioxidative properties of carnosine and other drugs. Biochem. Int. 20:1990;1097-1103.
14. Chen J., Petersen D.R., Schenker S., Henderson G.I. Formation of malondialdehyde adducts in livers of rats exposed to ethanol: role in ethanol-mediated inhibition of cytochrome c oxidase. Alcohol Clin. Exp. Res. 24:2000;544-552.
15. Chio K.S., Tappel A.L. Synthesis and characterization of the fluorescent products derived from malonaldehyde and amino acids. Biochemistry. 8:1969;2821-2826.
16. Comporti M. Lipid peroxidation and biogenic aldehydes: from the identification of 4-hydroxynonenal to further achievements in biopathology. Free Radic. Res. 28:1998;623-635.
17. Decker E.A. The role of phenolics, conjugated linoleic acid, carnosine, and pyrroloquinoline quinone as nonessential dietary antioxidants. Nutr. Rev. 53:1995;49-58.
18. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11:1991;81-128.
19. Forbes J.M., Soulis T., Thallas V., Panagiotopoulos S., Long D.M., Vasan S., Wagle D., Jerums G., Cooper M.E. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 44:2001;108-114.
20. Fu M.X., Wells-Knecht K.J., Blackledge J.A., Lyons T.J., Thorpe S.R., Baynes J.W. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 43:1994;676-683.
21. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine. Third Ed. 1999;Oxford University Press, Oxford, UK.
22. Hipkiss A.R., Preston J.E., Himswoth D.T., Worthington V.C., Abbot N.J. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci. Lett. 238:1997;135-138.
23. Hipkiss A.R., Worthington V.C., Himsworth D.T., Herwig W. Protective effects of carnosine against protein modification mediated by malondialdehyde and hypochlorite. Biochim. Biophys. Acta. 1380:1998;46-54.
24. Holliday R., McFarland G.A. A role for carnosine in cellular maintenance. Biochemistry (Mosc.). 65:2000;843-848.
25. Horning M.S., Blakemore L.J., Trombley P.Q. Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. Brain Res. 852:2000;56-61.
26. Hirsch J., Petrakova E., Feather M.S. The reaction of some dicarbonyl sugars with aminoguanidine. Carbohydr. Res. 232:1992;125-130.
27. Hirsch J., Petrakova E., Feather M.S., Barnes C.L. The reaction of D-glucose with aminoguanidine. Carbohydr. Res. 267:1995;17-25.
28. Ihm S.H., Yoo H.J., Park S.W., Ihm J. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats. Metabolism. 48:1999;1141-1145.
29. Kedziora-Kornatowska K., Luciak M. Effect of aminoguanidine on lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney. Biochem. Mol. Biol. Int. 46:1998;577-583.
30. Khalifah R.G., Baynes J.W., Hudson B.G. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. 257:1999;251-258.
31. Kochakian M., Manjula B.N., Egan J.J. Chronic dosing with aminoguanidine and novel advanced glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes. 45:1996;1694-1700.
32. Kohen R., Yamamoto Y., Cundy K.C., Ames B.N. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc. Natl. Acad. Sci. USA. 85:1988;3175-3179.
33. Kowluru R.A., Engerman R.L., Kern T.S. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine. Curr. Eye Res. 21:2000;814-819.
34. Lalich J.J., Paik W.C. Influence of hydralazine consumption on allylamine induced myocardial fibrosis and hypertrophy in rats. Exp. Mol. Pathol. 21:1974;29-39.
35. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging. 22:2001;187-194.
36. Makita Z., Vlassara H., Rayfield E., Cartwright K., Friedman E., Rodby R., Cerami A., Bucala R. Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science. 258:1992;651-653.
37. Munch G., Mayer S., Michaelis J., Hipkiss A.R., Riederer P., Muller R., Neumann A., Schinzel R., Cunningham A.M. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim. Biophys. Acta. 1360:1997;17-29.
38. Nelson T.J., Boor P.J. Allylamine cardiotoxicity - IV. Metabolism to acrolein by cardiovascular tissues. Biochem. Pharmacol. 31:1982;509-514.
39. Onorato J.M., Jenkins A.J., Thorpe S.R., Baynes J.W. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J. Biol. Chem. 275:2000;21177-21184.
40. Picard S., Parthasarathy S., Fruebis J., Witztum J.L. Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc. Natl. Acad. Sci. USA. 89:1992;6876-6880.
41. Reece P.A. Hydralazine and related compounds: chemistry, metabolism, and mode of action. Med. Res. Rev. 1:1981;73-96.
42. Reece P.A., Stafford I., Prager R.H., Walker G.J., Zacest R. Synthesis, formulation, and clinical pharmacological evaluation of hydralazine pyruvic acid hydrazone in two healthy volunteers. J. Pharm. Sci. 74:1985;193-196.
43. Reckelhoff J.F., Hennington B.S., Kanji V., Racusen L.C., Schmidt A.M., Yan S.D., Morrow J., Roberts L.J., Salahudeen A.K. Chronic aminoguanidine attenuates renal dysfunction and injury in aging rats. Am. J. Hypertens. 12:1999;492-498.
44. Requena J.R., Vidal P., Cabezas-Cerrato J. Aminoguanidine inhibits the modification of proteins by lipid peroxidation derived aldehydes: a possible antiatherogenic agent. Diabetes Res. 20:1992;43-49.
45. Serafini-Cesi F. Coversion of ally alcohol into acrolein by rat liver. Biochem. J. 128:1972;1103-1107.
46. Shapiro H.K. Carbonyl-trapping therapeutic strategies. Am. J. Ther. 5:1998;323-353.
47. Sies H. Antioxidants in disease: Mechanisms and therapy. Adv. Pharmacol. 38:1997;Entire volume.
48. Silva J.M., O'Brien P.J. Allyl alcohol- and acrolein-induced toxicity in isolated rat hepatocytes. Arch. Biochem. Biophys. 275:1989;551-558.
49. Soulis T., Cooper M.E., Vranes D., Bucala R., Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int. 50:1996;627-634.
50. Soulis T., Sastra S., Thallas V., Mortensen S.B., Wilken M., Clausen J.T., Bjerrum O.J., Petersen H., Lau J., Jerums G., Boel E., Cooper M.E. A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia. 42:1999;472-479.
51. Swamy-Mruthinti S., Green K., Abraham E.C. Inhibition of cataracts in moderately diabetic rats by aminoguanidine. Exp. Eye Res. 62:1996;505-510.
52. Uchida K., Stadtman E.R. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J. Biol. Chem. 268:1993;6388-6393.
53. Uchida K. Role of reactive aldehyde in cardiovascular diseases. Free Radic. Biol. Med. 28:2000;1685-1696.
54. Zhou S., Dickinson L.C., Yang L., Decker E.A. Identification of hydrazine in commercial preparations of carnosine and its influence on carnosine's antioxidative properties. Anal. Biochem. 261:1998;79-86.
55. Zhou S., Decker E.A. Ability of carnosine and other skeletal muscle components to quench unsaturated aldehydic lipid oxidation products. J. Agric. Food Chem. 47:1999;51-55.